Sign in

Daniel Grint

@danieljgrint.bsky.social
110 followers 125 following 72 posts

Associate Prof of Medical Statistics @lshtm.bsky.social | TB and HIV treatment trialist | Electronic health records analyst | Running shoe geek

PostsRepliesMedia
Reposted by Daniel Grint
The International Statistics & Epidemiology Group & Partnership @iseglshtm.bsky.social · 03/02/2026
📢Funded fellowships available📢 We have two fully funded medical statistics fellowships available for applicants from sub-Saharan Africa, covering ▶️1 yr MSc in Medical Statistics at LSHTM ▶️1 yr placement at a partnering research institution 🗓️Closing date 31st March www.lshtm.ac.uk/research/cen...
lshtm.ac.uk
International Statistics and Epidemiology Group | LSHTM
Collaborating with international research partners to improve health in low and middle-income countries
011
Reposted by Daniel Grint
Rein Houben @reinhouben.bsky.social · 07/10/2025
In a new preprint (NOT PEER REVIEWED) we continue to explore the challenge of overtreatment in community screening. It seems the benefits of TB treatment far outweigh the harms, especially once we accept that sputum culture is not perfect. Important food for thought. www.medrxiv.org/content/10.1...
medrxiv.org
Do no harm - re-evaluating the risks of overtreatment in community-wide tuberculosis screening
Background Community-wide screening is a crucial strategy to end tuberculosis (TB), but a common concern is potential harm from overtreatment following false positive diagnoses. However, current refer...
11210
Reposted by Daniel Grint
Clinical Infectious Diseases @cidjournal.bsky.social · 28/09/2025
Xpert MTB/RIF® cycle threshold as a marker of TB disease severity; Implications for TB treatment stratification ✅ Just Accepted #IDSky 🔗 bit.ly/3WbLI1G
1116
Daniel Grint @danieljgrint.bsky.social · 25/09/2025
This paper has now been peer reviewed and is available open access at CID.
doi.org
Xpert MTB/RIF® cycle threshold as a marker of TB disease severity; Implications for TB treatment stratification
Xpert MTB/RIF® and chest radiography at TB treatment initiation identify a majority of patients for whom a 4-month treatment duration is non-inferior to th
020
Daniel Grint @danieljgrint.bsky.social · 23/09/2025
apropos of nothing
jamanetwork.com
Acetaminophen Use During Pregnancy and Children’s Risk of Autism, ADHD, and Intellectual Disability
This nationwide cohort study with sibling control analysis examines the association of acetaminophen use during pregnancy with children’s risk of autism, ADHD, and intellectual disability.
020
Reposted by Daniel Grint
Matthew Saunders @mjsaunder.bsky.social · 09/09/2025
Nutritional status is a key determinant of TB. In this updated systematic review and dose-response meta-analysis (43 cohorts inc > 26 million people) we redefined the relationship between body mass index (BMI) and TB. doi.org/10.1093/ije/...
doi.org
Body mass index and tuberculosis risk: an updated systematic literature review and dose–response meta-analysis
AbstractBackground. The relationship between nutritional status and tuberculosis is critically important but poorly understood. We extended a 2009 review c
299
Reposted by Daniel Grint
Katherine Horton @kchorton.bsky.social · 05/09/2025
At a time when global resources for #TB research, development, prevention, and care are limited, which interventions should be prioritised in high burden settings? 📢 Our new pre-print compares the impact, cost, and cost-effectiveness of 9 TB interventions in 3 countries. 1/n bit.ly/3V3vXth
bit.ly
The potential impact, cost and cost-effectiveness of tuberculosis interventions - a modelling exercise
Background While a range of interventions exist for tuberculosis prevention, screening, diagnosis, and treatment, their potential population impact and cost-effectiveness are seldom directly compared,...
1119
Reposted by Daniel Grint
Alexander Luckmann @aluckmann.bsky.social · 20/08/2025
Academia may not give you job security, flexibility, or wealth, but it will let you unexpectedly connect to eduroam in foreign cities
301002164
Reposted by Daniel Grint
Emily Hunt @emily.space · 15/08/2025
I really dislike how science has started calling almost any fancy computational technique AI. 🧪 The framing of this entire article makes it sound like a benevolent AI independently made these drugs. That is *pure fantasy*. Instead: a team of scientists made a machine learning model for a study.

Article on BBC news. 
Title: AI designs antibiotics for gonorrhoea and MRSA superbugs
Description: Two new potential drugs have been designed by AI to kill drug-resistant bacteria, in a major Massachusetts Institute of Technology study.
572254695
Reposted by Daniel Grint
Peter MacPherson @petermacp.bsky.social · 01/05/2025
⚡️New preprint (not peer-reviewed)⚡️ In the SaDAPT trial with people with #HIV and #tuberculosis symptoms in 🇲🇼🇱🇸, we investigated if antiretroviral therapy should be initiated immediately, or delayed until TB results available. ssrn.com/abstract=523... Outcomes (incl. IRIS) similar across both arms.
The front page of the preprint article, showing title and authorsThe abstract of the preprintForest plot showing primary and secondary trial outcomes, with non-inferiority margins
156
Daniel Grint @danieljgrint.bsky.social · 18/07/2025
Delighted to see our long-acting injectible ART trial (IMPALA) presented at #IAS2025. 2-monthly injections are non-inferior to daily pill taking and overwhelmingly preferred. Next challenge is expanding access to LA ART; excellent news the WHO has recommended LA CAB+RPV in treatment guidelines.
131
Daniel Grint @danieljgrint.bsky.social · 05/07/2025
Describing the hawkeye automated line calling at Wimbledon as 'AI' can seriously get in the sea.
010
Daniel Grint @danieljgrint.bsky.social · 25/06/2025
🚨 NEW PRE-PRINT (currently going through peer review) We conducted a statistical simulation study to assess the impact of imperfect sensitivity and specificity, in the primary outcome definition of tuberculosis infection, in vaccine trials testing a non-inferiority hypothesis.
medrxiv.org
Imprecision in tuberculosis infection outcomes; implications for non-inferiority vaccine trials
Introduction Randomised trials comparing new vaccines against tuberculosis for use in neonates and infants, for whom Bacille Calmette-Guérin (BCG) vaccination is established practice, are using tuberc...
120
Reposted by Daniel Grint
Daniel Grint @danieljgrint.bsky.social · 13/06/2025
NEW PRE-PRINT (currently going through peer review) In this secondary analysis of the RIFASHORT trial we classified TB disease severity at baseline and show that for the majority of people 4-months of rifampicin-based treatment, without the use of a quinolone, was non-inferior to the 6-month SOC.
doi.org
Xpert MTB/RIF® cycle threshold as a marker of TB disease severity; Implications for TB treatment stratification
Introduction Recent trials have demonstrated that shortened four-month treatment durations are effective for the majority of people with tuberculosis (TB). However, there is a population of TB patient...
297
Daniel Grint @danieljgrint.bsky.social · 13/06/2025
NEW PRE-PRINT (currently going through peer review) In this secondary analysis of the RIFASHORT trial we classified TB disease severity at baseline and show that for the majority of people 4-months of rifampicin-based treatment, without the use of a quinolone, was non-inferior to the 6-month SOC.
doi.org
Xpert MTB/RIF® cycle threshold as a marker of TB disease severity; Implications for TB treatment stratification
Introduction Recent trials have demonstrated that shortened four-month treatment durations are effective for the majority of people with tuberculosis (TB). However, there is a population of TB patient...
297
Reposted by Daniel Grint
Tom Yates @tomayates.bsky.social · 20/05/2025
If you are at a loose end next Tuesday, come hear me and @danieljgrint.bsky.social talk about endpoints in TB trials Hybrid event, in London and online Most of the same ideas available in written form here www.thelancet.com/journals/lan... #IDSky #TBSky @sgschumacher.bsky.social
184
Daniel Grint @danieljgrint.bsky.social · 09/05/2025
020
Reposted by Daniel Grint
TB Centre LSHTM @tb-lshtm.bsky.social · 30/04/2025
Diary date: 27 May 12.45 BST "Defining efficacy endpoints for late phase tuberculosis treatment non-inferiority trials"@danieljgrint.bsky.social @tomayates.bsky.social www.lshtm.ac.uk/newsevents/e...
lshtm.ac.uk
Defining efficacy endpoints for late phase tuberculosis treatment
Randomised trials of new TB treatment regimens use a non-inferiority design, comparing new regimens to the established standard of care. In the last 20-years, these trials have used a composite
135
Reposted by Daniel Grint
Tim Morris @timpmorris.bsky.social · 29/04/2025
Oh good ‘ITT analyses are biased’ is back, here using the euphemism ‘diluted’ 🙃 The rules are that you have to: 1. say what your estimand is before saying an analysis is ‘diluted’/‘biased’ 2. admit that there are other reasonable estimands 3. describe how it could be realised in a future population
Screenshot from Angrist et al. 2025 NEJM evidence. The abstract says ‘Many randomized clinical trials fail to play out as intended: some participants assigned to the treatment group remain untreated, while others assigned to the control group cross over and receive treatment. In such settings…’ and I have highlighted ‘intention-to-treat analyses that compare participants by treatment assignment are diluted by noncompliance,’
5358
Daniel Grint @danieljgrint.bsky.social · 17/03/2025
Reposting for the Monday morning crowd
021
Daniel Grint @danieljgrint.bsky.social · 15/03/2025
It was a pleasure working with @tomayates.bsky.social on this comment in @lancetmicrobe.bsky.social It's time for new TB treatment trials to use a more focused primary outcome definition, moving on from the composite outcome that has prevailed for the last decade www.thelancet.com/journals/lan...
thelancet.com
Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes
Treatment regimens for tuberculosis remain protracted and burdensome, both for patients to adhere to and for health-care providers to administer. Particularly, many current regimens for drug-resistant...
172
Daniel Grint @danieljgrint.bsky.social · 12/03/2025
Phase I results often don't translate into proven efficacy in late phase trials, but once yearly PrEP against HIV is a tantalising prospect. Very promising.
021
Daniel Grint @danieljgrint.bsky.social · 10/02/2025
Interesting trial showing the effect of pre- and post-test counselling and cash transfers on TB treatment outcomes. LTFU outcomes lower in the intervention arm. Evidence that there is scope to improve outcomes beyond new drug regimens; no need to wait for a goldilocks regimen to solve everything.
110
Reposted by Daniel Grint
UCL Innovative Clinical Trials Unit @innovative-ctu.bsky.social · 22/01/2025
After falling for 10 years, rates of #tuberculosis in the UK are on the rise. 📈 Join the latest free webinar from @ucltb.bsky.social to discuss why this is happening, and how we can best respond. 📆 Thurs 6 February 🕒 3pm - 5pm 📍 Online Sign up now 👉 buff.ly/4agqAxE
Top right corner shows logos for UCL-TB and WHO Collaborating Centre on Tuberculosis Research and Innovation.

Text reads: TB in the UK. Thurs 6th Feb 2025.

Background shows graph with a falling and then rising trend and outline of the UK.
085
Daniel Grint @danieljgrint.bsky.social · 16/01/2025
<old man sigh> let's give this thing a try
170